Detalles de la búsqueda
1.
Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.
Invest New Drugs
; 36(1): 85-95, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28726132
2.
PA401, a novel CXCL8-based biologic therapeutic with increased glycosaminoglycan binding, reduces bronchoalveolar lavage neutrophils and systemic inflammatory markers in a murine model of LPS-induced lung inflammation.
Cytokine
; 76(2): 433-441, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26303011
3.
In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients.
CPT Pharmacometrics Syst Pharmacol
; 13(3): 359-373, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38327117
4.
Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat.
Mol Med
; 19: 79-87, 2013 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-23552722
5.
Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects.
Alzheimer Dis Assoc Disord
; 27(3): 278-86, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-22922591
6.
Population pharmacokinetic-pharmacodynamic analysis of givinostat.
Expert Opin Drug Metab Toxicol
; 19(4): 229-238, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37306105
7.
PK/PD analysis of trazodone and gabapentin in neuropathic pain rodent models: Translational PK-PD modeling from nonclinical to clinical development.
Clin Transl Sci
; 16(4): 606-617, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36785922
8.
Novel Thienoduocarmycin-Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies.
Mol Cancer Ther
; 22(12): 1465-1478, 2023 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37722716
9.
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.
Invest New Drugs
; 30(6): 2334-43, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22160853
10.
5-(2-amino-pyrimidin-4-yl)-1H-pyrrole and 2-(2-amino-pyrimidin-4-yl)-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one derivatives as new classes of selective and orally available Polo-like kinase 1 inhibitors.
Bioorg Med Chem Lett
; 22(1): 96-101, 2012 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22154349
11.
NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.
Bioorg Med Chem Lett
; 21(10): 2969-74, 2011 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21470862
12.
A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.
Nat Chem Biol
; 4(6): 357-65, 2008 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-18469809
13.
4,5-Dihydro-1H-pyrazolo[4,3-h]quinazolines as potent and selective Polo-like kinase 1 (PLK1) inhibitors.
Bioorg Med Chem Lett
; 20(22): 6489-94, 2010 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20932759
14.
Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.
Bioorg Med Chem
; 18(5): 1844-53, 2010 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20153204
15.
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
J Med Chem
; 59(7): 3392-408, 2016 Apr 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-27003761
16.
3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization.
J Med Chem
; 48(8): 2944-56, 2005 Apr 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-15828833
17.
Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.
Clin Cancer Res
; 9(8): 2957-64, 2003 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12912942
18.
3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding.
J Med Chem
; 47(13): 3367-80, 2004 Jun 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-15189033
19.
Correction to Discovery of Entrectinib: A New 3-Aminoindazole as a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
J Med Chem
; 62(17): 8364, 2019 Sep 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31424209
20.
CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study.
Curr Alzheimer Res
; 10(7): 742-53, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23968157